UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000032637
Receipt number R000037217
Scientific Title Prospective study for effectiveness of Etelcalcetide hydrochloride (Parsabiv) on patients treated with hemodialysis
Date of disclosure of the study information 2018/06/01
Last modified on 2023/05/22 15:24:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective study for effectiveness of Etelcalcetide hydrochloride (Parsabiv) on patients treated with hemodialysis

Acronym

Prospective study for effectiveness of Etelcalcetide on dialysis patients

Scientific Title

Prospective study for effectiveness of Etelcalcetide hydrochloride (Parsabiv) on patients treated with hemodialysis

Scientific Title:Acronym

Prospective study for effectiveness of Etelcalcetide on dialysis patients

Region

Japan


Condition

Condition

patients treated with hemodialysis

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Effectiveness of PARSABIV on QOL of dialysis patients and on the development of complication are studied prospectively. Check of leftover medicine.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase IV


Assessment

Primary outcomes

Change of QOL (every month)

Key secondary outcomes

Estimation od complication (every month)
CTR/ECG (every month)
bone mineral density and UCG(1 year later)
General blood test (every month)
Check of leftover medicine


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

Patients treating with hemodialysis for more than 12 months in dialysis clinic in Zenjinkai group

Key exclusion criteria

Patients decided as incompetent for this study by the doctor
Patietns showing contraindication for PARSABIV
Patients showing low Ca(<8.4) before admonistration of PARSABIV
Patients having malignant diseases
Patients having serious diseases in liver, kidney (other than CRF), and heart.
Patients treated with cinacalcet or bisphosphonate

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Ashio
Middle name
Last name Yoshimura

Organization

Zenjinkai Shinyokohama Daiichi Clinic

Division name

Division of Nephrology

Zip code

222-0033

Address

ShinyokohamaChitosekannkoBLG 8F,3-6-4 Shinyokohama,kouhoku-ku,Yokohama

TEL

045-477-3412

Email

shinyokohd@gmail.com


Public contact

Name of contact person

1st name Ashio
Middle name
Last name Yoshimura

Organization

Zenjinkai Shinyokohama Daiichi Clinic

Division name

Division of Nephrology

Zip code

222-0033

Address

ShinyokohamaChitosekannkoBLG 8F,3-6-4 Shinyokohama,kouhoku-ku,Yokohama

TEL

045-477-3412

Homepage URL


Email

shinyokohd@gmail.com


Sponsor or person

Institute

Zenjinkai Shinyokohama Daiichi Clinic
Division of Nephrology

Institute

Department

Personal name

Ashio Yoshimura


Funding Source

Organization

Zenjinkai Shinyokohama Daiichi Clinic
Division of Nephrology

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Yokohama Daiichi Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Zenjinkai Shinyokohama Daiichi Clinic

Address

ShinyokohamaChitosekannkoBLG 8F,3-6-4 Shinyokohama,kouhoku-ku,Yokohama

Tel

045-477-3412

Email

shinyokohd@gmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 06 Month 01 Day


Related information

URL releasing protocol

The study has discontined.

Publication of results

Unpublished


Result

URL related to results and publications

none

Number of participants that the trial has enrolled

20

Results

The study has discontinued.

Results date posted

2023 Year 05 Month 22 Day

Results Delayed


Results Delay Reason

The study has discontinued.

Date of the first journal publication of results


Baseline Characteristics

The study has discontinued.

Participant flow

The study has discontinued.

Adverse events

none

Outcome measures

The study has discontinued.

Plan to share IPD

The study has discontinued.

IPD sharing Plan description

The study has discontinued.


Progress

Recruitment status

Preinitiation

Date of protocol fixation

2018 Year 03 Month 31 Day

Date of IRB


Anticipated trial start date

2018 Year 06 Month 01 Day

Last follow-up date

2020 Year 05 Month 31 Day

Date of closure to data entry

2020 Year 05 Month 31 Day

Date trial data considered complete

2021 Year 03 Month 31 Day

Date analysis concluded

2021 Year 08 Month 31 Day


Other

Other related information

Change of QOL of patients after start of PARSABIV.
Blood chemistry including iPTH will be also
studied.


Management information

Registered date

2018 Year 05 Month 18 Day

Last modified on

2023 Year 05 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037217


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name